uniQure Announces FDA Acceptance and Priority Review of the Biologics License Application for ifezuntirgene inilparvovec for the Treatment of Huntington’s Disease

<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css" /><p align="center" style="text-align:center;"><em>~ FDA sets PDUFA target action date of May 1, 2027 ~</em><p align="center" style="text-align:center;"><em>~ If approved, ifezuntirgene inilparvovec will be the world’s first disease-modifying...